(2R)-1-[(Tert-Butoxy)Carbonyl]-2-Methylpyrrolidine-2-Carboxylic Acid

How does α-methyl-D-proline incorporation alter conformational rigidity in macrocyclic peptide design?

Solid-phase peptide synthesis (SPPS) of macrocyclic pharmacophores frequently demands γ- and β-turn stabilization that linear sequences cannot achieve without non-proteinogenic amino acids. (2R)-1-[(Tert-butoxy)carbonyl]-2-methylpyrrolidine-2-carboxylic acid, as a protected quaternary α-amino acid, introduces Φ and Ψ dihedral angle constraints that mimic a cis-amide geometry observed in type VIa β-turns. Its α-methyl substituent increases the rotational barrier around the C_α–N bond to approximately 25–30 kcal·mol⁻¹, effectively locking the pyrrolidine ring into an endo envelope pucker. In Boc/Bzl solid-phase protocols on Merrifield resin with 0.8–1.2 mmol/g loading, the sterically hindered acid is pre-activated with 3.0 equiv. of HATU and 4.5 equiv. of DIPEA in DMF at 0 °C for 12–18 min before coupling, yet the quaternary carboxylate exhibits 30–40% slower acylation kinetics compared to proline, necessitating double-coupling cycles monitored by Kaiser test to achieve a yield above 98.5%. A synthetic compliance framework aligned with ICH Q7 for active pharmaceutical ingredient (API) starting materials mandates residual solvent analysis per USP <467>, with a deprotection cocktail of 1.5% TFA, 2.5% triisopropylsilane, and 5% dichloromethane (v/v) applied in a flow-through reactor at 25±2 °C for selective N^α-Boc cleavage without affecting the acid-labile side-chain protections. The resultant macrocyclic pentapeptide—often a somatostatin or integrin α₅β₁ antagonist—exhibits a plasma half-life extension from 2 h to 18 h when the (2R)-2-methylproline residue replaces an L-proline in the ring, as documented in published stability assays under simulated intestinal fluid at 37 °C. End-use finished dosage forms include lyophilized powders for subcutaneous injection, where residual palladium (from earlier Cbz hydrogenolysis steps) must not exceed 10 ppm per ICH Q3D Elemental Impurities guidelines, and the final cyclic peptide purity verified by reversed-phase UPLC with > 99.0% area normalization at 214 nm.

Protease inhibitor P2 fragment construction with a sterically congested proline surrogate

Hepatitis C virus NS3/4A and SARS-CoV-2 3CL protease inhibitor scaffolds often rely on a macrocyclic topology where the P2 proline residue determines the trajectory of the P1–P3 backbone. Direct incorporation of native proline leads to proteolytic susceptibility and conformational heterogeneity, while (2R)-1-[(tert-butoxy)carbonyl]-2-methylpyrrolidine-2-carboxylic acid supplies the necessary 2,2-disubstituted pyrrolidine core found in clinical candidates like grazoprevir. A typical solution-phase amidation employs 1.05–1.15 equiv. of the Boc-acid activated via ethyl chloroformate mixed anhydride method in dichloromethane at -20 °C in the presence of N-methylmorpholine (1.3 equiv.); the acyloxycarbonium intermediate undergoes a rearrangement to the unreactive urethane by-product if the temperature rises above -10 °C, reducing coupling efficiency by up to 45%. Therefore, jacket-cooled reactors with a temperature drift of ±3 °C and inline FTIR monitoring for anhydride formation at 1810 cm⁻¹ are mandated during scale-up. Compliance with REACH Annex XVII requires that the Boc-deprotection waste stream (TFA/isobutylene) be quenched with 5 M NaOH to pH 7.5–8.5 before disposal, while ICH M7 control of mutagenic impurities demands screening for isobutylene-derived alkyl sulfonates below the threshold of toxicological concern (1.5 µg/day). The crystalline P2 fragment, after silica gel chromatography with ethyl acetate/hexane (3:7 v/v) and recrystallization from IPA/water, exhibits differential scanning calorimetry endotherms at 141.2 °C (onset) with >99.5% diastereomeric excess confirmed by chiral SFC. Final API synthesis integrates this building block into a 16–18 membered macrocycle via ring-closing metathesis with Grubbs II catalyst (5 mol%), where the quaternary proline methyl group minimizes N-alkylation side reactions during the subsequent N-sulfonamide formation at the P2 position. Finished dosage forms include film-coated tablets requiring dissolution testing in pH 6.8 phosphate buffer with ≥75% release after 30 min per FDA 21 CFR 314 guidance.

Within kilogram-scale campaigns for an oral HCV NS3/4A protease inhibitor, the (2R)-1-Boc-2-methylproline building block passes through a three-stage boronic acid-freeze-thaw degas workflow prior to a mixed pivaloyl anhydride activation. The steric shielding of the carboxylic acid by the gem-dimethyl motif of the Boc group necessitates 1.8 equiv. of pivaloyl chloride and 2.5 equiv. of DIPEA in acetonitrile/THF (4:1) at -30 °C, forming a transient anhydride with a half-life of 7–9 min before coupling to the amino-ester hydrochloride. Process analytical technology using ReactIR confirms complete activation via disappearance of the carboxylate peak at 1605 cm⁻¹. Residual palladium from an earlier Buchwald–Hartwig amination on the P3 subunit must not exceed 5 ppm, verified by ICP-MS on a crashed-out intermediate slurry from 2-methyltetrahydrofuran/heptane antisolvent crystallization. The resulting dipeptide fragment, after trituration with 0.2 M HCl and brine, is submitted to a Boc cleavage with 4 M HCl in 1,4-dioxane at 10±3 °C, during which the methyl substituent suppresses carbocation rearrangement that typically forms des-methyl impurities. Regulatory starting material designation per ICH Q11 requires a complete impurity fate and purge study for the seven-step synthetic sequence, where the (2R)-Boc-acid is introduced at Step 4 and its enantiomeric excess maintained at ≥99.8% by chiral purity release testing using a CHIRALPAK® IG column with heptane/ethanol/trifluoroacetic acid (90:10:0.1).

When a chiral secondary amine catalyst is liberated from this N-Boc-pyrrolidine precursor

Deprotection of (2R)-1-[(tert-butoxy)carbonyl]-2-methylpyrrolidine-2-carboxylic acid with anhydrous 4 M HCl in cyclopentyl methyl ether yields the hydrochloride salt of (R)-2-methylproline, which upon neutralization with 1.02 equiv. of triethylamine in acetonitrile generates a homogeneous organocatalyst applied in enantioselective aldol additions. The catalyst loading of 10–15 mol% in DMSO at 5 °C promotes reaction between 4-nitrobenzaldehyde (0.5 M) and neat acetone (5.0 equiv.) to furnish (R)-4-hydroxy-4-(4-nitrophenyl)butan-2-one with enantiomeric excess reported in the range of 72–84% at ≥85% conversion after 48 h. The α-methyl substituent sterically desymmetrizes the enamine intermediate, favoring si-facial attack more effectively than unsubstituted proline, though the retro-aldol rate increases with prolonged reaction times above 60 h. In a continuous-flow packed-bed reactor configuration, the Boc-acid is first immobilized on Merrifield resin via its carboxylate and then deprotected on-column, creating a heterogeneous catalyst bed with a turnover number exceeding 120. Enantiomeric purity requirements for exported intermediates invoke USP <621> methodology with Chiralpak AD-H column at 25 °C and a mobile phase of hexane/isopropanol/diethylamine (85:15:0.05). The finished chiral β-hydroxy ketone product, destined for beta-blocker synthesis, must contain less than 0.10% of the corresponding dehydration product and be stored under argon at -20 °C. Standard shelf-life stability guidelines prescribed by ISO 6353-3 for reagents and the absence of residual pyrrolidine derivatives (limit 25 ppm) govern quality conformance in business-to-business supply agreements.

Reference standard qualification for accurate chromatographic purity assignment of α,α-disubstituted amino acids

When analytical reference materials are prepared from (2R)-1-[(tert-butoxy)carbonyl]-2-methylpyrrolidine-2-carboxylic acid for external standard quantitation, the minimum purity threshold is set at 99.5% by qNMR with 1,3,5-trimethoxybenzene as internal standard. Chromatographic purity protocols under Ph. Eur. 2.2.29 employ a C18 column (150 × 4.6 mm, 3.5 µm) with a gradient of acetonitrile/0.1% phosphoric acid from 20:80 to 90:10 over 25 min, where the main peak elutes at 13.7±0.2 min, and any single unknown impurity is limited to <0.10%. For chiral purity assignment, the reference standard is dissolved at 1.0 mg/mL in methanol/water (50:50) and injected on a CHIRALPAK® IA-3 column with ethanol/acetonitrile/trifluoroacetic acid (50:50:0.1) at a flow rate of 0.5 mL/min, where the (S)-enantiomer elutes at a relative retention time of 1.18 and is controlled at <0.15%. A batch release certificate referencing ISO 17034 ensures traceability to the SI unit; the certified value for the assay is determined by mass balance subtracting organic impurities (HPLC), water (Karl Fischer titration, limit 0.3%), residual solvents (GC headspace, acetonitrile <410 ppm), and sulfated ash (<0.05%). The lyophilized powder, dispensed into amber vials under nitrogen, must undergo a homogeneity assessment of 10 random units with an RSD of assay values below 0.5% before it qualifies as a secondary pharmacopoeial standard. In stability-indicating mode, forced degradation with 0.1 M HCl at 70 °C for 6 h produces the des-Boc degradant, which is chromatographed and used as a system suitability marker to confirm resolution >2.5 between the Boc-acid and its decarboxylated analogue. This reference standard supports the cGMP release of peptidomimetic drug substances manufactured across multiple contract manufacturing sites, where pharmacopoeial compliance with USP <561> and ICH Q2(R1) validation of analytical procedures is mandatory.

Chiral resolution of racemic N-Boc-2-methylproline constitutes a decisive cost driver in securing the (2R)-enantiomer for structural biology and medicinal chemistry campaigns. Simulated moving bed (SMB) chromatography on a Licosep 8-450 unit equipped with eight columns packed with CHIRALPAK® IA (20 µm) stationary phase resolves the enantiomers using acetonitrile/0.1% trifluoroacetic acid (85:15) as desorbent. Feed concentration is maintained at 35 g·L⁻¹, with a feed flow rate of 1.8 mL·min⁻¹ and a switch time of 0.9 min, yielding a productivity of 1.5 kg of racemate per kg of CSP per day. The (2R)-enantiomer elutes as the raffinate stream with an optical purity of 99.2% ee, while the extract stream containing the (2S)-enantiomer is racemized in a separate loop through enolate formation with 1.1 equiv. of LDA in THF at -78 °C, followed by a proton quench with 2.0 equiv. of acetic acid, achieving 87% racemization yield. Coupling of the SMB purification with continuous racemization reduces overall waste by 42% compared to diastereomeric salt resolution with (1R,2R)-pseudoephedrine. Industrial-scale qualification of the resulting (R)-Boc-acid requires ion chromatography to confirm that TFA counterion residues are below 25 ppm and that heavy metals per ICH Q3D are within parenteral limits. The isolated powder is further micronized to a D₉₀ of <50 µm in a jet mill under nitrogen to ensure dissolution consistency when used in manual or automated solid-phase peptide synthesizers operating with a scale of up to 50 mmol per batch. This SMB-derived material directly feeds into research-supply pipelines for integrin receptor ligation assays and for X-ray co-crystallography studies requiring milligram amounts of conformationally locked peptide ligands with Bolton–Hunter derivatization readiness.